In humanized mouse models, Tessera is demonstrating LNP delivery of gene writers to, and rewriting of, hematopoietic stem cells to an extent that could be curative in sickle cell disease

CEO Mike Severino describes the sickle cell data Tessera is presenting at #ASGCT2024, and highlights the company's gene writing platform and programs more broadly.